The present invention relates to a combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor selected from the group consisting of a compound of formula (I) or a compound of formula (II), or pharmaceutically acceptable salt thereof, (b) a 17alpha-Hydroxylase/ C17,20-lyase inhibitor (CYP17 inhibitor), specifically abiraterone acetate and 1-(2-Chloro-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one or pharmaceutically acceptable salt thereof, for simultaneous, separate or...

The invention provides a combination of a) a compound of Formula (Ia): or a pharmaceutically acceptable salt thereof, and b) abiraterone or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.

Pharmaceutical composition comprising abiraterone acetate, which exhibits a reduced food effect and improved bioavailability.

Provided are acetatic Abiraterone trifluoroacetate, a preparation method and an application of same. The acetatic Abiraterone trifluoroacetate is obtained through a salt-forming reaction between acetatic Abiraterone and trifluoroacetic acid. The acetatic Abiraterone trifluoroacetate undergoes self-purification through recrystallization, and dissociation and recrystallization are performed on the purified acetatic Abiraterone trifluoroacetate, so that obtained acetatic Abiraterone has a high puri...